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The concept of a carbimazole embryopathy underlies current Endocrine Society advice to avoid this drug in early pregnancy,
favouring propylthiouracil as an alternative for the treatment of maternal hyperthyroidism. We aimed to establish whether
suspected spontaneous reporting of adverse drug reactions in the UK via the Yellow Card Scheme supports a carbimazole embry-
opathy and the lack of association between propylthiouracil and congenital anomalies. All birth defects related to maternal
treatment with carbimazole or propylthiouracil reported over a 47-year period via the Yellow Card Scheme were analysed. 57 cases
with 97 anomalies were reported following in utero exposure to carbimazole. These anomalies included aplasia cutis, choanal
atresia, tracheo-oesophageal fistula, and patent vitellointestinal duct, which have previously been reported in association with
carbimazole/methimazole exposure in utero. Only 6 cases with 11 anomalies were reported for propylthiouracil, all within the
last 15 years. Therefore, these findings may support a carbimazole embryopathy. There are few birth defects associated with pro-
pylthiouracil, but this should be interpreted in the context of higher historical prescription rates for carbimazole.
1. Introduction
Hyperthyroidism, primarily caused by Graves’ disease, aﬀects
about 1 in 500 pregnancies. Although not common, it is
important to recognise and treat maternal hyperthyroidism,
because failing to do so can have detrimental eﬀects. In the
mother, untreated hyperthyroidism can cause spontaneous
miscarriage, pregnancy induced hypertension, preterm la-
bour, congestive cardiac failure, and thyroid storm; for the
fetus this could mean still birth, intrauterine growth restric-
tion, or low birth-weight [1]. Further, hyperthyroid states in
the mother have been associated with congenital anomalies
including oesophageal atresia, tracheo-oesophageal fistula,
and biliary tree atresia [2, 3].
There is also an association between the antithyroid
drugs used to treat maternal hyperthyroidism and congenital
anomalies. This association ismost widely reported for carbi-
mazole and its active metabolite, methimazole, such that the
concept of a carbimazole embryopathy is being increasingly
acknowledged amongst prescribing clinicians [4–9]. There
has been no convincing link between the alternative thion-
amide drug propylthiouracil and birth defects [10] despite
the rate of placental transfer of the drug being the same as
that of carbimazole [11]. Both drugs are equally eﬃcacious
at controlling maternal hyperthyroidism [12]. This has led
to the Endocrine Society’s current advice to use propy-
lthiouracil as a first-line drug during pregnancy, if availa-
ble, especially during first trimester organogenesis [13].
Carbimazole or methimazole should be used only if propy-
lthiouracil is not available or if the patient cannot tolerate or
has an adverse response to it [13].
Recognition of serious adverse eﬀects of anti-thyroid
drugs in pregnancy is dependent upon reporting of such
eﬀects by prescribing clinicians. Since 1964, the Yellow Card
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Scheme has allowed healthcare professionals involved in
prescribing in the UK to report suspected serious adverse
drug reactions (ADRs) to the Commission on Human Medi-
cines (CHM)/Medicines andHealthcare Products Regulatory
Agency (MHRA). The professional reporting the suspected
ADR submits a Yellow Card found at the back of the British
National Formulary, or electronically via the MHRAwebsite,
giving brief clinical details supporting their suspicions that
the drug is responsible for the adverse outcome(s) seen. In
addition, pharmaceutical companies are legally required to
report suspected serious ADRs of their products. Since Octo-
ber 2005, patients have also been able to report suspected
ADRs through the Yellow Card Scheme.
In this paper, we aimed to establish whether spontaneous
reporting via the Yellow Card Scheme in the UK lends sup-
port to an association between congenital anomalies and the
use of carbimazole or propylthiouracil in pregnancy.
2. Methods
Data on all birth defects reported via the Yellow Card Scheme
in association with treatment with carbimazole or propy-
lthiouracil between July 1963 and September 2010 was ob-
tained in “Drug Analysis Prints” from the MHRA [14]. Drug
Analysis Prints give a complete listing of all UK sponta-
neous suspected ADRs reported through the Yellow Card
Scheme by healthcare professionals, patients, and the phar-
maceutical industry to the MHRA and CHM. They do not
present a complete overview of the risks associated with
specific medicines, and conclusions on the safety and risks
of medicines cannot be made on the information contained
in Drug Analysis Prints alone.
3. Results
The Drug Analysis Print from the MHRA included 64 re-
ports of birth defects following exposure to antithyroid
drugs, reported between 1963 and 2010. Of these, 54 reports
came from healthcare professionals, 9 from pharmaceutical
companies, and one from a patient. On review, one of the re-
ports was found not to comprise birth defect and was ex-
cluded from further analysis.
Figure 1 shows the total numbers of birth defects re-
ported following exposure to carbimazole and propylthiou-
racil by decade. For carbimazole, there have been 57 cases
with a total of 97 congenital anomalies. Three (5%) of these
cases (with tracheo-oesophageal fistula, anencephaly, and
unspecified congenital heart disease, respectively) have been
reported as fatal. For propylthiouracil, only 6 cases with 11
congenital anomalies have been reported, but these have all
been within the last 15 years. None of the six cases has been
reported as fatal.
Table 1 describes the type of birth defects reported for
carbimazole and propylthiouracil exposure in utero and the
number of defects seen in conjunction with other anomalies
in the same individual. Two-thirds of the cases with birth
defects associated with both carbimazole and propylthiou-
racil exposure had multiple anomalies in the same individ-
uals. Birth defects associated with carbimazole exposure in-
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Figure 1: Bar graph showing number of cases with congenital
malformations reported following exposure to carbimazole or
propylthiouracil by decade from 1965 until 2010.
cluded aplasia cutis, choanal atresia, tracheo-oesophageal
fistula, patent vitellointestinal duct, and dysmorphic facies,
which have been previously reported as components of car-
bimazole embryopathy [9]. The doses of carbimazole used
were known for 34 out of 57 cases (60%), and ranged be-
tween 5mg and 60mg daily (median 15mg). Similarly, the
dose of propylthiouracil, known for 5 out of 6 cases (83%),
ranged widely from 50mg to 350mg daily (median 50mg).
4. Discussion
Our results support an association between exposure to car-
bimazole in utero and birth defects. There have been far few-
er reports via the Yellow Card Scheme of birth defects re-
lated to propylthiouracil exposure, but all the reports relat-
ed to this drug have been within the last 15 years; this may
reflect the fact that historically carbimazole has been the
more widely prescribed drug in the UK [15], rather than
it its rate of teratogenicity being significantly higher. There
has been a 3.5-fold increase in PTU prescription relative
to carbimazole since 1981 in the UK [15], which may have
unmasked adverse eﬀects that had previously gone unno-
ticed. Changes in prescribing trends are also reflected by
data from the USA, where between 2002 and 2008, propyl-
thiouracil use increased in women of childbearing age [16].
The teratogenicity of anti-thyroid drugs remains a source
of controversy [17]. Two previous studies comparing car-
bimazole with propylthiouracil showed no diﬀerence in the
number of major congenital anomalies seen in babies ex-
posed to these drugs in utero [12, 18]. However, both studies
were relatively small. A study from Sweden found 4 reports
between 1995–2000 of infants born with oesophageal atresia
and omphalocele or choanal atresia, 3 of whom had been ex-
posed to methimazole in the first trimester; there was no as-
sociation between these anomalies and propylthiouracil [19].
A recent larger case control study which included over 18,000
cases with congenital malformations, 127 of whom were
exposed to antithyroid drugs in the first trimester, showed
a significant association between exposure to carbimazole/
methimazole and choanal atresia or omphalocele [20]. For
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Table 1: Suspected adverse drug reactions of congenital anomalies associated with carbimazole and propylthiouracil received via the UK
Yellow Card Scheme.
Carbimazole Propylthiouracil
System Congenital anomalies∗
Number of
anomalies
(total)
Number with
single
anomaly
Number with
other
anomalies
Number of
anomalies
(total)
Number with
single
anomaly
Number
with other
anomalies
Skin Aplasia cutis 6 2 4 0 0 0
Other (skin disorder, ulcer) 2 0 2 0 0 0
Respiratory Choanal atresia 5 2 3 0 0 0
Tracheo-oesophageal fistula 2 2 0 0 0 0
Other (neonatal respiratory
distress syndrome, respiratory
disorder)
2 0 2 0 0 0
Gastrointestinal Cleft palate 5 3 2 1 1 0
Omphalocele/umbilical
abnormalities
4 2 2 2 0 2
Patent vitellointestinal duct 1 0 1 0 0 0
Duodenal atresia 1 1 0 0 0 0
Anal atresia 1 0 1 0 0 0
Other (neonatal jaundice and
abnormal liver function tests)
2 0 2 0 0 0
Not specified 3 2 1 0 0 0
Cardiovascular Septal defects 3 1 2 0 0 0
Other (Fallot’s tetralogy and
coarctation of aorta)
2 2 0 0 0 0
Not specified 1 0 1 0 0 0
Musculoskeletal Limb/hand/foot malformation 4 1 3 3 1 2
Not specified 4 3 1 0 0 0
Neurological Spina bifida 3 1 2 0 0 0
Hydrocephalus 5 1 4 0 0 0
Anencephaly 4 4 0 1 0 1
Hypotonia 2 0 2 0 0 0
Other (spine malformation and
holoprosencephaly)
1 0 1 1 0 1
Renal/urinary
tract
Renal aplasia 1 0 1 0 0 0
Other (urinary tract
malformation, epispadias)
1 0 1 1 1 0
Endocrine Thyroid disorder 1 0 1 0 0 0
Hypogonadism 1 0 1 0 0 0
Craniofacial Dysmorphic facies 2 0 2 1 0 1
Skull malformation 4 1 3 0 0 0
Ear malformation 3 1 2 0 0 0
Deafness 4 2 2 0 0 0
Eye malformation 4 1 3 0 0 0
Other (nose malformation and
teeth malformation)
2 0 2 0 0 0
Others
Nipple/breast anomalies (athelia
and hypoplastic nipples)
2 0 2 0 0 0
Developmental delay 2 0 2 0 0 0
Autism 0 0 0 1 0 1
Not specified 7 1 6 0 0 0
Total 97 33 64 11 3 8
∗One Yellow Card report may contain more than one reaction term. Therefore, the total number of reactions is greater than the total number of reports.
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propylthiouracil, there was a tentative suggestion of an asso-
ciation with situs inversus, renal agenesis, or dysgenesis and
cardiac outflow tract malformations although these were
not as strong as the associations reported for carbimazole
[20]. Consistent with these observations, we found five cases
of choanal atresia and four cases of umbilical anomalies
associated with carbimazole exposure in our study (Table 1).
There were no reports of situs inversus, renal agenesis, or car-
diac malformations associated with propylthiouracil expo-
sure (Table 1).
The nature of congenital malformations seen in our cas-
es is wide ranging, keeping with previous reports of birth
defects related to these drugs (Table 1). Several of the congen-
ital malformations associated with carbimazole exposure ob-
served in this study, including aplasia cutis, choanal atresia,
tracheo-oesophageal fistula, omphalocele, patent vitelloin-
testinal duct, nipple abnormalities, and dysmorphic facies,
have previously been reported in association with carbima-
zole/methimazole exposure in utero [9]. Furthermore, two-
thirds of the anomalies associated with carbimazole exposure
occurred with other defects in the same cases, lending further
support to an embryopathy as opposed to a single malforma-
tion which might have occurred spontaneously irrespective
of exposure to teratogens or not. It should be noted that most
of the anomalies seen following propylthiouracil exposure
also did not occur in isolation, but given the small numbers
for propylthiouracil, this should be interpreted with caution.
We acknowledge that there are several limitations to
our study. Firstly, true prevalence of birth defects related to
carbimazole and propylthiouracil cannot be calculated from
the information we have collated. We do not know the total
number of births to mothers with Graves’ disease over the
study period, and we do not have data relating to the types of
anti-thyroid drugs prescribed to pregnant women over the
study period. In addition, Yellow Card data cannot be used
as a reliable indicator of the frequency of suspected ADRs
to medicines. The number of reports received via the Yellow
Card Scheme does not directly equate to the number of peo-
ple who suﬀer adverse reactions to drugs. It is recognised that
this scheme is associated with an unknown and variable level
of underreporting. The level of ADR reporting may fluc-
tuate between given years due to a variety of reasons, for ex-
ample, a medicine being new, stimulated interest/publicity,
and variations in exposure to the medicine. In this case, there
is potential for bias in that prescribers may be more like-
ly to make an association between a congenital anomaly and
carbimazole given previous reports of an embryopathy relat-
ed to the drug which is not the case for propylthiouracil.
Similarly, carbimazole and propylthiouracil were introduced
to the market at diﬀerent times, and therefore, reporting bias
means that they should not be directly compared.
Secondly, causality cannot be proven. It is important to
note that a report of an ADR does not necessarily mean
that it was caused by the drug. Many factors have to be tak-
en into account in assessing causal relationships including
temporal association, the possible contribution of concomi-
tant medication, and the underlying disease. We do not have
information on maternal thyroid function for our cases;
this is important, because maternal hyperthyroidism itself is
associated with congenital anomalies [2, 3]. Furthermore, in
a cohort study of infants of mothers with Graves’ disease,
the incidence of congenital malformations was significantly
higher in infants whose mothers were hyperthyroid in the
first trimester compared to those who were euthyroid, with
a reported prevalence of 6% and 0.3% in the two groups,
respectively [21].
Thirdly, we do not have a complete data on the doses and
durations of the carbimazole or propylthiouracil exposure
in our cases. We only know doses used for 60% of patients
treated with carbimazole and 83% of patients treated with
propylthiouracil.
Nevertheless, themultiple characteristic congenital anom-
alies we have reported in this study lend support to the ter-
atogenicity of thionamide drugs, in particular carbimazole.
This has important clinical implications, and prescribing
physicians should be aware of the potential association with
congenital anomalies whilst balancing this risk with that of
uncontrolled maternal hyperthyroidism in pregnancy.
5. Conclusion
The evidence we have described in this study may support a
carbimazole embryopathy. There are few birth defects asso-
ciated with propylthiouracil, but this should be interpreted
in the context of higher historical prescription rates for car-
bimazole.
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